上海赛伦生物技术股份有限公司2025年度业绩快报公告

Financial Data Summary - The company reported total revenue of 196.21 million RMB, a year-on-year increase of 0.66% [2] - Operating profit reached 62.04 million RMB, reflecting a growth of 19.34% compared to the previous year [2] - Total profit amounted to 61.74 million RMB, showing a year-on-year increase of 22.10% [2] - Net profit attributable to the parent company was 51.71 million RMB, up 16.76% year-on-year [2] - Net profit attributable to the parent company after deducting non-recurring gains and losses was 42.56 million RMB, with a significant increase of 50.65% [2][5] Financial Position - As of the end of the reporting period, total assets were 1.16 billion RMB, an increase of 3.83% from the beginning of the period [3] - Equity attributable to the parent company was 1.11 billion RMB, which is a 1.56% increase from the beginning of the period [3] Factors Influencing Performance - The slight increase in revenue was attributed to the initial sales phase of the rabies serum launched in the second half of 2025, which did not contribute significantly to revenue during the reporting period [4] - The growth in net profit was primarily due to the reduction of investment losses recognized from the associated company, Shanghai Saiyuan Biotechnology Co., Ltd., and a decrease in non-recurring gains and losses, as well as a reduction in R&D expenses [4]